Please login to the form below
medicines use
This page shows the latest medicines use news and features for those working in and with pharma, biotech and healthcare.
EMA to support real-world monitoring of COVID-19 treatments/vaccines
New infrastructure will support real-world studies. The European Medicines Agency (EMA) has set up new infrastructure to support the use of real-world monitoring of potential treatments and vaccines for ... Another contract, agreed in June, saw the EMA
Latest news
-
Shionogi launches thrombocytopenia treatment Mulpleo in the UK
The UK’s medicines watchdog NICE and the Scottish Medicines Consortium recently backed the use of Mulpleo in this patient population after determining that the drug was cost-effective. ... Earlier this month, NICE also published final draft guidance
-
Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations
Mayzent (siponimoid), developed by Swiss pharma Novartis, has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of ... Safety reviews of Lemtrada and
-
NICE backs first cannabis-based drugs, both from GW Pharma
Approved to treat patients with epilepsy and multiple sclerosis. Two cannabis-based medicines have been approved for use on the NHS in England for the first time, and will be used ... for rigorously tested, evidenced and regulatory approved
-
Personalised medicine can improve treatment, but access still an issue
path. This benefits both patients and healthcare systems – the aim of personalised and precision medicines is to decrease the use of ineffective medicines in specific patient populations. ... For the NHS, access to these medicines means working with
-
Sanofi/Regeneron wins another EU approval for Dupixent
Treatment with Dupixent also resulted in a significant reduction (74%) of systemic corticosteroid use and the need for sino-nasal surgery (83%) compared to the placebo group. ... Dupixent is already approved in the US for use with other medicines to
More from news
Approximately 0 fully matching, plus 262 partially matching documents found.
Latest Intelligence
-
The global antibiotic crisis: a 2020 perspective
drugs on a trial basis – de-linking the valuation and reward payments from the medicines’ usage. ... by 2024. The plan also supports increased use of a ‘precision medicines’ approach increasing the percentage of prescriptions informed by
-
Keeping up the fight against HIV and using the lessons to tackle other threats
of medicines to use. ... We make sure the science is understood and we use that feedback to make sure our medicines are available and used in the right way.
-
The evolution of real-world studies
We appreciate that our partnership with the FDA has allowed us to take a significant step forward in the use of real-world data to bring medicines to patients who are ... Real-world data is playing an increasingly important role in expanding the use of
-
The UK’s new medicines pricing deal – opportunities and risks for pharma
over time to health gain relative to expenditure on new medicines across the NHS”. ... What is missing, however, is a reference to the comparisons to other countries on medicines use that was in the 2014 PPRS.
-
Happy 70th birthday NHS: the next 70 need to be very different
It also seems to be relatively efficient, with low admin costs and high use of cheaper generic medicines, and also performs well in managing long-term illnesses, such as diabetes. ... That partnership, it is hoped, will create trust – and some
More from intelligence
Approximately 1 fully matching, plus 37 partially matching documents found.
Latest appointments
-
New hires at Bayer, Eisai and Accord Healthcare
Prior to joining Accord, Grosso held a number of senior public and commercial roles, including the role of principal medicines management pharmacist at UCL Hospitals. ... Grosso is also a registered pharmacist, and has a long-standing interest in the
-
ABPI Scotland appoints Sandra Auld as director
the access to and use of new and innovative medicines for Scottish patients. . ... and innovative medicines.”.
-
EFPIA's Richard Torbett to move to the ABPI
team. “His experience in both government and the pharmaceutical industry will prove invaluable when addressing the issues of access and use of new medicines in the NHS and in leading discussions
-
EAHP elects Joan Peppard as president
As president of the EAHP, Peppard will look to advance the organisation's mission to develop hospital pharmacy in order to promote the best and safest use of medicines and medical
-
ABPI appoints value and access manager
Rowland will work on a range of projects to improve patient access to innovative medicines, in line with the ABPI's strategic objectives around health technology assessment and market access. ... greater use of newer medicines,” added Catchpole.
More from appointments
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest from PMHub
-
World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer
Targeted therapies for ovarian cancer. In 2011, the European Medicines Agency (EMA) approved the use of targeted therapies, including an anti-angiogenic treatment alongside chemotherapy to increase the effectiveness of treatment ... Zejula. Available at:
-
NHS medicines optimisation milestone
by 2020/21 if the NHS embraces the use of best value biological medicines in a proactive, systematic and safe way’. ... The best biologics agenda and pharma. In line with the Commissioning Framework for Biological Medicines, NHS England, NHS
-
Patient Engagement and Experience Conference, 16-17 May
The conference brings together HCPs, patients, payers, government, pharma and industry under one roof to focus on patients’ engagement and experience of their treatment to improve the real-world use of ... medicines.Speaking at the conference .
-
"Legal highs" ruling leaves illegal labs laughing
There is a huge amount of off-label use of licensed medicines by medically qualified prescribers. ... There are also many agents that have crossed the line from illegal to legal use, such as cannabinoids for MS, as well as previously approved medicines
-
Making good practice common practice in rare disease
Good listeners use a number of techniques - here are two simple examples you can try yourself:. ... Researchers found that the size of the drawing predicted speed of return to work, cardiac anxiety, use of alternative medicines and number of phone calls
More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Could formulary intelligence be your brand differentiator?
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Porterhouse Medical strengthens its senior management team
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...
Latest intelligence
- Could formulary intelligence be your brand differentiator?
- Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
Quick links
Infographics
